News

Q2 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

Q2 2025 allergy news highlights include FDA actions on HAE therapies, warnings for antihistamines, and new sinus surgery guidelines for chronic rhinosinusitis.

A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.

Our June 2025 recap highlights significant advancements in cardiology, including new drug approvals and pivotal trial results.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in eyecare.

The results of the ZENITH trial have encouraged the expansion of sotatercept’s label to patients with prior background therapy.

Breakthroughs in narcolepsy, idiopathic hypersomnia, OSA, and RLS signal a shift toward personalized care and novel therapies. Check out this June 2025 sleep month in review.

The month in review spotlights renal regulatory news and clinical trial data as well as coverage of the 62nd European Renal Association Congress.

A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.

The month in review spotlights hepatic regulatory news, new clinical trial data, and novel research about liver disease risk factors.

Our Q2 2025 recap for ophthalmology highlights 5 regulatory updates, 5 important trial announcements, and top perspectives in eyecare.

June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

The month in review spotlights perspectives on collaborative GI care, updates in C diff, and new research about disorders of gut brain interaction.

The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.

Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

Chang explains the importance of collaboration between gastroenterologists and allergists in EoE care and praises recent ACG guidelines on disease management.

This Month in Review summary includes a list of some of the most impactful news in the dermatology space from June 2025.

June was characterized by HCPLive’s coverage of the AOA 2025 Conference in Minneapolis and a host of cross-specialty disease indicators and drug uses.

The CRL cited deficiencies previously identified at a third-party manufacturing vendor unrelated to OLC, and the Company plans to request a Type A meeting.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

This 4-year data highlights dupilumab’s efficacy among children under the age of 12 with atopic dermatitis.

At SDPA 2025, Theodore Rosen, MD, discussed various psychological disorders, including delusions of parasitosis, excoriation disorder, dermatitis artefacta, and others.

Maria Hordinsky, MD, spoke at SDPA regarding her talk highlighting a variety of clinical pearls for spotting scarring alopecia early.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

In her SDPA interview, Maria Hordinsky, MD, spoke about her session regarding clinical pearls for clinicians seeking to spot alopecia early in patients.

At SDPA 2025, Spizuoco discussed how trichoscopic signs like black dots, yellow dots, and exclamation hairs guide treatment decisions.